New study tracks Real-World safety of adzynma for rare blood clotting disorder
NCT ID NCT07353099
First seen Jan 22, 2026 · Last updated May 09, 2026 · Updated 13 times
Summary
This study looks at the safety of a drug called Adzynma in people with a rare inherited blood disorder (congenital TTP). The main goals are to see how many patients develop allergic reactions or antibodies that stop the drug from working. Researchers will review medical records from about 50 children and adults who received Adzynma in regular care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.